Key Takeaways Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound ...
The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...
The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...
Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...
4d
Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...
The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in ...
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...
The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating ...
Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
Eli Lilly and Company (NYSE: LLY) shares are trading higher Monday. The upward momentum in the stock comes after the FDA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback